Fidson Healthcare Plc has reported a significant 41% increase in revenue, reaching ₦119.06 billion for the 2025 financial year.
This growth was primarily fueled by a 41.5% jump in ethical drug sales, which rose to ₦77.8 billion from ₦55.0 billion in 2024.
The company’s audited financial statements, released for the year ending December 31, 2025, reflect strong demand across its product portfolio despite a challenging macroeconomic climate characterized by rising costs and currency volatility.
The company’s profitability showed even more remarkable improvement, with profit before tax climbing 94% to ₦14.96 billion, up from ₦7.7 billion the previous year.
Profit after-tax also surged by 125% to ₦9.88 billion.
On the strength of these results, Fidson has proposed a dividend of ₦3.6 billion, translating to ₦1.50 per share, an increase from the ₦1.00 per share distributed in 2024. Earnings per share also saw a substantial rise, moving from 192 kobo to 412 kobo.
However, the path to these gains was marked by significant cost pressures. Finance costs increased by approximately 30% to ₦7.13 billion, driven by the issuance of commercial papers at high interest rates exceeding 23%.
Additionally, the company recorded a net foreign exchange loss of ₦6.01 billion, highlighting the continued vulnerability of pharmaceutical firms that rely heavily on imported inputs. Tax expenses also spiked by over 80%, reaching ₦4.25 billion.
Fidson’s balance sheet reflects a strategic effort to manage debt while reinvesting earnings. Interest-bearing loans fell by 48.7% to ₦3.60 billion, though the current portion of loans saw a 15.9% increase.
Total equity grew by 35% to ₦30.2 billion, supported by a 47.1% rise in retained earnings. This bolstered capital position is expected to help the company reduce its reliance on expensive debt financing in the future.